2021 •
Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
Authors: Constantinos G. Neochoritis; Marco A. Velasco-Velázquez; Matthew Groves; Alexander Dömling; Yingying Cong; Nilima Dinesh Kumar; Fulvio Reggiori; Rick Oerlemans; Jolanda Smith; Angel J Ruiz-Moreno
Venue: RSC Medicinal Chemistry
Type: Publication
Abstract: α-Ketoamide HCV protease inhibitors covalently bind to SARS-CoV-2 3CLpro. Boceprevir is a particular promising repurposed drug as it potently inhibits cellular viral proliferation.
We have placed cookies on your device to help make this website and the services we offer better. By using this site, you agree to the use of cookies. Learn more